| Literature DB >> 33503876 |
Vincenzo De Falco1, Stefania Napolitano1, Daniela Esposito2, Luigi Pio Guerrera1, Davide Ciardiello1, Luigi Formisano2, Teresa Troiani1.
Abstract
Cutaneous melanoma is considered a rare tumor, although it is one of the most common cancers in young adults and its incidence has risen in the last decades. Targeted therapy, with BRAF and MEK inhibitors, and immunotherapy revolutionized the treatment of metastatic melanoma but there is still a considerable percentage of patients with primary or acquired resistance to these therapies. Recently, oncology researchers directed their attention at the role of long non-coding RNAs (lncRNAs) in different types of cancers, including melanoma. lncRNAs are RNA transcripts, initially considered "junk sequences", that have been proven to have a crucial role in the fine regulation of physiological and pathological processes of different tissues. Furthermore, they are more expressed in tumors than protein-coding genes, constituting perfect candidates either as biomarkers (diagnostic, prognostic, predictive) or as therapeutic targets. In this work, we reviewed all the literature available for lncRNA in melanoma, elucidating all the potential roles in this tumor.Entities:
Keywords: biomarkers; cancer therapy; lncRNA; melanoma; skin cancer
Mesh:
Substances:
Year: 2021 PMID: 33503876 PMCID: PMC7865742 DOI: 10.3390/ijms22031166
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923